> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arvinas Moves First Data From Its Immune-Cancer Degrader To Late 2027, A Year Later
- URL: https://www.bullished.co/arvinas-moves-first-data-from-its-immune-cancer-degrader-to-late-2027-a-year-later-292570fc/
- Published: 2026-11-03T22:16:43.000Z
- Updated: 2026-11-03T22:16:43.000Z
- Description: The drug developer's 10-Q also shows Pfizer's research deal ended and a $0.5 million revenue quarter, with cash at $558.9 million.
- Author: Matteo Parrino
- Tags: SEC Filings, ARVN, Industry: Healthcare

[Arvinas](https://www.bullished.co/tag/arvn/), a clinical-stage biotech that develops protein-degrading drugs, now says it will present [initial monotherapy data](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069464/arvn-20260930.htm?ref=bullished.co) from its ARV-6723 cancer trial in the second half of 2027, according to its quarterly report filed Tuesday. The [prior quarter's report](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026052554/arvn-20260630.htm?ref=bullished.co) had promised data from the same trial in the second half of 2026.

## A year added to the timeline

ARV-6723 is an oral drug designed to degrade HPK1, a protein that dampens immune attack on tumors. It would be Arvinas's debut in immuno-oncology, and no other HPK1 degrader has reached U.S. clinics.

The earlier filing said Arvinas was "planning to complete this Phase 1 monotherapy dose escalation clinical trial and share clinical data in the second half of 2026." The new one says only that it plans to present initial monotherapy data in the second half of 2027\. Dosing in a cohort combining ARV-6723 with pembrolizumab is expected to begin in mid-2027.

Enrollment in the first cohort is limited to patients previously treated with an immune checkpoint inhibitor who lack suitable standard therapies. Arvinas said in its [earnings release](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069101/q32026earningsrelease.htm?ref=bullished.co) that it will show new preclinical ARV-6723 data at the Society for Immunotherapy of Cancer meeting, Nov. 4-8.

## Revenue gone, profit a one-time artifact

Third-quarter revenue fell to $0.5 million, all Rigel royalties on the breast cancer drug VEPPANU, from $41.9 million a year earlier. The quarterly net loss was $53.9 million, against $35.1 million a year earlier.

The nine-month profit of $57.9 million rests on deal accounting. When Arvinas and Pfizer licensed VEPPANU to Rigel in the second quarter, the company booked $126.4 million of net revenue by recognizing remaining deferred Pfizer revenue. That item cannot repeat.

Two partnerships have ended: Genentech's in August and Pfizer's research tie-up in October. Cash, cash equivalents, restricted cash and marketable securities were $558.9 million at September 30, down from $567.9 million at June 30, and the company still says that funds operations into the second half of 2028.

## Near-term data dates

Arvinas has submitted ARV-393 lymphoma data to the American Society of Hematology meeting, Dec. 12-15\. It also plans to file a clinical trial application in the European Union in the fourth quarter for ARV-102, which targets progressive supranuclear palsy.

The FDA has placed the planned U.S. trial of ARV-102 in that disease on clinical hold, and the company says discussions continue. Arvinas had a market value of $492 million at Tuesday's report time.

The next test of the pipeline is ARV-393's lymphoma data at the hematology meeting in December.

### Sources

- [10-Q Filing — Arvinas (ARVN)](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069464/arvn-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Arvinas (ARVN), Q2 FY2026 filed 2026-08-04 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026052554/arvn-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, q32026earningsrelease.htm) — Arvinas, filed 2026-11-03](https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069101/q32026earningsrelease.htm?ref=bullished.co) — SEC EDGAR

### More on Arvinas

- [Arvinas Stock Plunges 7%, Wiping Out $35 Million, As Licensing Revenue Dries Up In Third-Quarter Loss](https://www.bullished.co/arvinas-stock-plunges-7-wiping-out-35-million-as-licensing-revenue-dries-up-in-third-99cdfc83/)
- [Arvinas Third-Quarter Revenue Falls To $0.5 Million From $41.9 Million As Pfizer Income Ends](https://www.bullished.co/arvinas-third-quarter-revenue-falls-to-0-5-million-from-41-9-million-as-pfizer-income-ends-6d7998ca/)
- [Arvinas CEO Sets 30% Response Bar For Its First Lymphoma Data In December](https://www.bullished.co/arvinas-ceo-sets-30-response-bar-for-its-first-lymphoma-data-in-december-9e064e48/)

[All Arvinas (ARVN) coverage →](https://www.bullished.co/tag/arvn/)